- Academic Registry
Programme & Unit Catalogues


BB50248: Cancer genetics and therapy

[Page last updated: 15 October 2020]

Follow this link for further information on academic years Academic Year: 2020/1
Further information on owning departmentsOwning Department/School: Department of Biology & Biochemistry
Further information on credits Credits: 15      [equivalent to 30 CATS credits]
Further information on notional study hours Notional Study Hours: 300
Further information on unit levels Level: Masters UG & PG (FHEQ level 7)
Further information on teaching periods Period:
Academic Year
Further information on unit assessment Assessment Summary: CW 50%, EX 50%
Further information on unit assessment Assessment Detail:
  • Therapy-Related Research Presentation (CW 50%)
  • Synoptic Written Examination (EX 50%)
Further information on supplementary assessment Supplementary Assessment:
Like-for-like reassessment (where allowed by programme regulations)
Further information on requisites Requisites:
Description: Aims:
The unit aims to provide students knowledge of contemporary cancer research and the challenges and opportunities in developing treatments for cancer.

Learning Outcomes:
By the end of this unit you will be able to:
* Apply broad knowledge gained from current literature to compare the molecular and micro-environmental differences of cancer and normal tissues
* Demonstrate an integrative and critically evaluative approach to analyse how these differences are exploited in drug design for conventional and rationalised cancer therapies
* Critically evaluate and communicate the findings from cutting-edge research publications in cancer genetics and therapy through formal presentation.

Content:
Topics include the genetic hallmarks of cancer development including oncogenesis (oncogenes/tumour suppressor genes/viral oncogenesis), angiogenesis, metastasis, metabolic reprogramming, cancer stem cell niches. This will followed by exploration of the latest research in treatments for cancer, including conventional (radio/chemotherapy) and rationalised treatments, such as immunotherapies etc.
Further information on programme availabilityProgramme availability:

BB50248 is Optional (DEU) on the following programmes:

Department of Biology & Biochemistry
  • RSBB-AFM50 : Integrated PhD Molecular Biosciences (Medical Biosciences)
  • TSBB-AFM50 : MSc Molecular Biosciences (Medical Biosciences)

Notes:

  • This unit catalogue is applicable for the 2020/21 academic year only. Students continuing their studies into 2021/22 and beyond should not assume that this unit will be available in future years in the format displayed here for 2020/21.
  • Programmes and units are subject to change in accordance with normal University procedures.
  • Availability of units will be subject to constraints such as staff availability, minimum and maximum group sizes, and timetabling factors as well as a student's ability to meet any pre-requisite rules.
  • Find out more about these and other important University terms and conditions here.